2-Pyridone THRβ Agonist Crystal Forms for Stability

Resolve Bottlenecks,
Find Innovative Solutions
Generate Solutions

Solution Overview

Problem

Existing thyroid hormone receptor agonists face challenges with reduced THRβ biological activity, THRβ/THRα selectivity, poor pharmacological stability, and poor pharmacokinetic effects, making it difficult to develop effective drugs for metabolic diseases.

Innovation Solution

A new 2-pyridone derivative with high agonist activity and selectivity on thyroid hormone β receptor, formulated in crystalline forms A, B, C, D, E, and F, exhibiting good stability, low hygroscopicity, and minimal heat influence, is developed for treating metabolic diseases.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If pyridazinone ring structural modifications are made based on MGL-3196, then some pharmacological activity is maintained, but THRβ biological activity and THRβ/THRα selectivity are reduced

Engineering Contradiction:
ImproveTHRβ biological activityVSAvoidTHRβ/THRα selectivity
Core Design Contradiction:
ReliabilityVSAdaptability or versatility

Solution Approach 1:

The patent changes the fundamental structural parameters by replacing the pyridazinone ring with a pyridone ring, and further modifies the pyridone ring by replacing the nitrogen atom with a carbon atom. This series of parameter changes results in compounds that maintain pharmacological activity while improving THRβ/THRα selectivity and metabolic stability.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

Instead of modifying the pyridazinone ring structure as done in prior art, the patent inverts the approach by completely changing the ring type to pyridone and then further inverting by replacing the nitrogen with carbon. This inversion strategy leads to improved selectivity and stability.

Inventive Principle:
Principle #13The other way round (Inversion)

2Adaptability or versatility

If nitrogen atom on pyridone is replaced, then structural modification is achieved, but pharmacological activity is lost and stability becomes extremely poor

Engineering Contradiction:
Improvestructural modificationVSAvoidpharmacological activity and stability
Core Design Contradiction:
Adaptability or versatilityVSReliability

Solution Approach 1:

The patent carefully controls the parameter change by replacing the nitrogen atom with a carbon atom at specific positions (positions 1 or 2 of the pyridone ring) while maintaining the overall pyridone scaffold. This controlled parameter change achieves structural modification while preserving pharmacological activity and metabolic stability.

Inventive Principle:
Principle #35Parameter changes

3Reliability

If crystalline forms with high stability are developed, then pharmacokinetic properties are improved, but manufacturing complexity increases

Engineering Contradiction:
Improvestability and pharmacokinetic propertiesVSAvoidmanufacturing complexity
Core Design Contradiction:
ReliabilityVSDevice complexity

Solution Approach 1:

The patent changes the physical state parameter by developing multiple crystalline forms ( Forms 1-6) with different crystal structures. Each crystalline form has distinct X-ray powder diffraction patterns and thermal properties. This parameter change improves stability and pharmacokinetic properties while providing options for manufacturing.

Inventive Principle:
Principle #35Parameter changes

Solution Approach 2:

The patent utilizes phase transitions by preparing multiple crystalline forms through different crystallization processes. The compounds can be transformed between different crystalline phases, and the patent provides specific crystallization conditions for obtaining each form, thereby improving stability without excessive manufacturing complexity.

Inventive Principle:
Principle #36Phase transitions

Data Source

PatentEP4631943A1Thyroid hormone ß receptor agonist, crystal form, preparation method and use
Publication Date: 2025.10.15 KPC PHARM INC
  • EP4631943A1 patent drawingFigure 1
  • EP4631943A1 patent drawingFigure 2~3
  • EP4631943A1 patent drawingFigure 4

AI summary

The present disclosure belongs to the field of medicines. Disclosed in the present invention are a thyroid hormone β receptor agonist, a crystalline form, a preparation method and the use. The compound is a compound having a structural formula as represented by formula (I) or a pharmaceutically acceptable salt thereof. The X-ray powder diffraction pattern of a crystal form A of the compound of formula (I) comprises characteristic peaks at 6.10 ± 0.20°, 12.08 ±0.20° and 16.49±0.20° 2θ, as determined by means of using Cu-Ka radiation, The present invention develops a new 2-pyridone derivative. The compound has high agonistic activity and selectivity for the thyroid hormone β receptor, and can be used for treating metabolic diseases, particularly for treating diseases related to thyroid hormone receptor. The present invention also studies a series of crystal forms of the compound. The crystal form A compound has the advantages of good stability, low hygroscopicity, and small heat influence.